NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis $21.12 -0.21 (-0.98%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$21.06 -0.05 (-0.26%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CPRX alerts:Sign Up Key Stats Today's Range$20.81▼$21.2550-Day Range$20.75▼$26.3152-Week Range$15.34▼$26.58Volume999,536 shsAverage Volume1.21 million shsMarket Capitalization$2.58 billionP/E Ratio13.45Dividend YieldN/APrice Target$32.83Consensus RatingBuy Company Overview Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida. Read More Catalyst Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreCPRX MarketRank™: Catalyst Pharmaceuticals scored higher than 98% of companies evaluated by MarketBeat, and ranked 31st out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCatalyst Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Catalyst Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth12.11% Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 12.11% in the coming year, from $1.90 to $2.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 13.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 13.45, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.67.Price to Earnings Growth RatioCatalyst Pharmaceuticals has a PEG Ratio of 0.87. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 3.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Catalyst Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.31% of the outstanding shares of Catalyst Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 9.18%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-1.99 Percentage of Shares Shorted7.31% of the outstanding shares of Catalyst Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 9.18%, indicating that investor sentiment is decreasing significantly. News and Social Media4.0 / 5News Sentiment1.18 News SentimentCatalyst Pharmaceuticals has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Catalyst Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest23 people have searched for CPRX on MarketBeat in the last 30 days. This is an increase of 21% compared to the previous 30 days.MarketBeat Follows4 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,879,369.00 in company stock.Percentage Held by Insiders10.40% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Catalyst Pharmaceuticals' insider trading history. Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Stock News HeadlinesCatalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gainsJuly 30 at 10:25 AM | marketwatch.comInvestors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen enviable returns of 404% over the past five yearsJuly 29, 2025 | finance.yahoo.comDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts warn a programmable dollar could erase your privacy and control your spending. A free guide reveals how to protect your savings before the system goes live.August 2 at 2:00 AM | American Alternative (Ad)Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025July 22, 2025 | globenewswire.comCatalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gainsJuly 16, 2025 | marketwatch.comWhy Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term - NasdaqJuly 9, 2025 | nasdaq.comCatalyst Pharmaceuticals, Inc. (CPRX) Cash Flow - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comCatalyst Pharmaceuticals is Now Oversold (CPRX) - NasdaqJuly 2, 2025 | nasdaq.comSee More Headlines CPRX Stock Analysis - Frequently Asked Questions How have CPRX shares performed this year? Catalyst Pharmaceuticals' stock was trading at $20.87 at the beginning of 2025. Since then, CPRX shares have increased by 1.2% and is now trading at $21.12. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 EPS for the quarter, meeting the consensus estimate of $0.10. The biopharmaceutical company earned $35.95 million during the quarter, compared to analyst estimates of $34.47 million. Catalyst Pharmaceuticals had a net margin of 36.91% and a trailing twelve-month return on equity of 42.45%. Read the conference call transcript. Who are Catalyst Pharmaceuticals' major shareholders? Top institutional shareholders of Catalyst Pharmaceuticals include Allianz Asset Management GmbH (0.85%), Aberdeen Group plc (0.56%), Gables Capital Management Inc. (0.34%) and DekaBank Deutsche Girozentrale (0.15%). Insiders that own company stock include Patrick J Mcenany, Steve Miller, David S Tierney, Donald A Denkhaus, Richard J Daly, Brian Elsbernd, Philip H Coelho, Gary Ingenito, Alicia Grande, Preethi Sundaram, Carmen Jeffrey Del and Molly Harper. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings11/09/2021Today8/01/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CPRX CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees80Year Founded2002Price Target and Rating Average Price Target for Catalyst Pharmaceuticals$32.83 High Price Target$36.00 Low Price Target$30.00 Potential Upside/Downside+55.5%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$1.57 Trailing P/E Ratio13.45 Forward P/E Ratio11.12 P/E Growth0.87Net Income$163.89 million Net Margins36.91% Pretax Margin48.34% Return on Equity42.45% Return on Assets36.59% Debt Debt-to-Equity RatioN/A Current Ratio6.14 Quick Ratio5.96 Sales & Book Value Annual Sales$491.73 million Price / Sales5.24 Cash Flow$2.42 per share Price / Cash Flow8.72 Book Value$6.10 per share Price / Book3.46Miscellaneous Outstanding Shares121,970,000Free Float109,290,000Market Cap$2.58 billion OptionableOptionable Beta0.70 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CPRX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.